Friday, July 10, 2026

pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib

Sun Yat-sen University

Sun Yat-sen University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Safety of Almonertinib, Subjects With Hyperuricemia, Renal Function Disorder, Acute-O

广州市新港西路135号, CN HQ
3,680 Employees
NMPA registrant Type
Company details
Status
Public
HQ
广州市新港西路135号, CN
Employees
3,680
Programs
19
Drugs
25
Patents
0
Clinical program

Palliative Chemotherapy

Phase 3 · small molecule · Colorectal Neoplasms Malignant

Palliative Chemotherapy for Colorectal Neoplasms Malignant is a Phase 3 program (small_molecule) at Sun Yat-sen University with 1 ClinicalTrials.gov record(s).

← All Sun Yat-sen University projects Phase 3 small molecule active

Internal code DECIDE-CRLM-10

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sun Yat-sen University
Phase
Phase 3
Modality
small_molecule
Indication
Colorectal Neoplasms Malignant
Status
active
Trials
1